Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure

Background

Program Overview

The Impact of Iron Deficiency in Chronic Heart Failure

ID vs Anemia in CHF

Prevalence of ID in Patients With CHF

ID Is Common Irrespective of Ethnicity, Sex, or Anemia Status

Causes of ID in CHF -- Absolute and Functional

Common Iron Deficit in Patients With CHF

Impact of ID in Patients With CHF

Impact of ID in Patients With CHF (cont)

ID Impairs Mitochondrial Function

Summary

Treating Iron Deficiency in Chronic Heart Failure

Correction of ID as a Therapeutic Target in HF

FAIR-HF: Study Design

FAIR-HF: Co-Primary Endpoints

FAIR-HF: 6MWT Secondary Endpoint

CONFIRM-HF: Study Design

CONFIRM-HF: Primary Endpoint

EFFECT-HF: Study Design

EFFECT-HF: Primary Endpoint Change in Peak VO2

Meta-Analysis: Time to First Event Outcomes

Oral Iron Replacement Does Not Work in HF

ESC Guidelines for the Diagnosis and Treatment of HF

Recent and Ongoing Trials in Iron Replacement Therapy

4 Ongoing Large RCTs in Patients With HF

AFFIRM-AHF

FAIR-HF2

HEART-FID

IRONMAN

Potential Mechanism of Action of IV Iron

Effect of ID and Iron Supplementation on Cardiomyoctye Function

Summary

Iron Deficiency in Chronic Heart Failure Across the Spectrum of Ejection Fraction

Classification of HF According to EF

Prevalence of ID Across EF Spectrum of HF

ESC Recommendations Largely For HFrEF

Most Trial Data Based on Patients With HFrEF

Ongoing Trials With IV FCM in HF

Conclusion

Does Ejection Fraction Matter?

Diagnosing Patients With HFpEF

Managing Patients With HFpEF

Effect of ID on Patients With HFpEF

The Need for Trials on Patients With HFpEF and ID

FAIR-HFpEF Trial

FAIR-HFpEF Trial (cont)

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)